Biden’s cancer charity raised millions, yet spent nothing on finding a cure for the disease.
But the organization did spend money on staff and travel.
In fact, the Biden Cancer Initiative raised $4.8 million, but spent nothing on research.
The story first broke when the New York Post received a copy of the public tax filings of the charity.
They noted that the executive suite of the group had received large salaries, but spent no money on its stated goals to “develop and drive implementation of solutions to accelerate progress in cancer prevention, detection, diagnosis, research and care and to reduce disparities in cancer outcomes.”
Joe Biden’s son died from a rare form of brain cancer, so the family created the charity to “spare other families the pain of their loss.” But like other Biden promises, this one was also hollow.
The organization’s president, Gregory Simon – who is also a former Pfizer executive and lobbyist – saw his salary double to over $400,000 when he took the job.
The group spent over $150,000 on travel in two years and over $700,000 for various conferences.
Most of their efforts seemed to “raise awareness of the disparities in cancer outcomes,” but like many liberal talking-points, didn’t actually do anything but make the “woke” elite feel good about themselves.
The initiative suspended operations in 2019 when Biden’s presidential aspirations became more important than pretending to fight cancer.
Gregory Simon told the Associated Press in 2019:
‘Today, we are suspending activities given our unique circumstances. We remain personally committed to the cause, but at this time will have to pause efforts, We tried to power through but it became increasingly difficult to get the traction we needed to complete our mission.’
While the charity did take in millions from direct contributions, the bulk of its funding was in the form of partnerships and indirect pledges.
In other words, the group was a money laundering operation and passthrough for companies and organizations to promote other initiatives.
Ironically, the Trump administration did a great deal for families battling rare forms of cancer by allowing the fast-tracking of so-called “orphan drugs” and signing “right to try” legislation which allows people to use non-FDA approved therapies.